Rosano, GMC;
Tamargo, J;
Kjeldsen, KP;
Lainscak, M;
Agewall, S;
Anker, SD;
Ceconi, C;
Coats, AJS;
Drexel, H;
Filippatos, G;
et al.
Rosano, GMC; Tamargo, J; Kjeldsen, KP; Lainscak, M; Agewall, S; Anker, SD; Ceconi, C; Coats, AJS; Drexel, H; Filippatos, G; Kaski, JC; Lund, L; Niessner, A; Savarese, G; Schmidt, TA; Seferovic, P; Wassmann, S; Walther, T; Lewis, BS
(2018)
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Eur Heart J Cardiovasc Pharmacother, 4 (3).
pp. 180-188.
ISSN 2055-6845
https://doi.org/10.1093/ehjcvp/pvy015
SGUL Authors: Kaski, Juan Carlos
![[img]](https://openaccess.sgul.ac.uk/109814/1.hassmallThumbnailVersion/pvy015.pdf) ![](https://openaccess.sgul.ac.uk/109814/1.haspreviewThumbnailVersion/pvy015.pdf) Preview |
|
PDF
Accepted Version
Available under License ["licenses_description_publisher" not defined].
Download (954kB)
| Preview
|
Abstract
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard end-points. RAASi are also the basis in treatment of arterial hypertension and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit. RAASi therapy, however, is associated with an increased risk of hyperkalaemia. Patients with chronic kidney disease and HF are at increased risk of hyperkalaemia and ∼50% of these patients experience two or more yearly recurrences. A substantial proportion of patients receiving RAASi therapy have their therapy down-titrated or more often discontinued even after a single episode of elevated potassium (K+) level.
Item Type: |
Article
|
Additional Information: |
This is a pre-copyedited, author-produced version of an article accepted for publication in European Heart Journal - Cardiovascular Pharmacotherapy following peer review. The version of record Giuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, Mitja Lainscak, Stefan Agewall, Stefan D Anker, Claudio Ceconi, Andrew J S Coats, Heinz Drexel, Gerasimos Filippatos, Juan Carlos Kaski, Lars Lund, Alexander Niessner, Gianluigi Savarese, Thomas A Schmidt, Petar Seferovic, Sven Wassmann, Thomas Walther, Basil S Lewis; Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with RAAS-inhibitors - Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology, European Heart Journal - Cardiovascular Pharmacotherapy, , pvy015, is available online at: https://doi.org/10.1093/ehjcvp/pvy015 |
SGUL Research Institute / Research Centre: |
Academic Structure > Molecular and Clinical Sciences Research Institute (MCS) |
Journal or Publication Title: |
Eur Heart J Cardiovasc Pharmacother |
ISSN: |
2055-6845 |
Language: |
eng |
Dates: |
Date | Event |
---|
1 July 2018 | Published | 3 May 2018 | Published Online | 26 April 2018 | Accepted |
|
Publisher License: |
Publisher's own licence |
PubMed ID: |
29726985 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/109814 |
Publisher's version: |
https://doi.org/10.1093/ehjcvp/pvy015 |
Statistics
Item downloaded times since 10 May 2018.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |